SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

JANUMET

MRK·Merck & Co., Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already marketed. Generic versions of Janumet XR launched in July 2026, and generic Janumet (non-XR) received FDA ANDA approval in 2026. The brand faces ongoing revenue erosion from generics and IRA-mandated price cuts effective January 1, 2027.
Why 3/10
Janumet is an already-approved, commercially marketed drug with no pending PDUFA or pivotal readout. The defining binary events (generic entry, patent cliff) have already occurred. The next notable date is the IRA price cut taking effect January 1, 2027, but this is a gradual commercial headwind, not a binary catalyst. Janumet is also a small and declining portion of Merck's $66B+ revenue base, so even major sales swings move the stock minimally.
Actionable Insight BEARISH

Janumet is a post-peak, generically-eroded asset with no binary catalysts ahead. The IRA price cut on January 1, 2027, will further compress brand revenue, but this is well-telegraphed. For MRK investors, the focus should remain on Keytruda's Qlex launch trajectory, Gardasil demand in China, and pipeline readouts rather than the declining diabetes franchise, which is already a diminishing contributor to overall results.

Price Chart

Loading chart...

Executive Summary

Janumet (sitagliptin/metformin) is Merck's long-approved combination diabetes pill that is now deep into its patent cliff. Generic versions launched in mid-2026, combined Januvia/Janumet franchise sales are declining roughly 30% year-over-year, and an IRA-mandated 85% Medicare price cut takes effect in January 2027. For Merck, a $144B market-cap diversified pharma giant, Janumet is a small and shrinking revenue stream. The stock's trajectory is driven far more by Keytruda, Gardasil, and the pipeline than by this declining legacy diabetes brand.

How It Works

Janumet is a combination pill containing two diabetes drugs: sitagliptin (a DPP-4 inhibitor that increases insulin release when blood sugar rises) and metformin (which lowers glucose production in the liver and improves insulin sensitivity). It is taken orally to manage type 2 diabetes alongside diet and exercise.

Trial Status

Janumet (immediate-release) and Janumet XR (extended-release) are both FDA-approved and have been commercially marketed for many years. No new pivotal clinical trials are underway for the brand; the drug is in its post-patent lifecycle phase.

The Two-Sided Case

▲ Bull Case4
Janumet remains a meaningful revenue contributor: combined Januvia/Janumet franchise still generated ~$940M in Janumet sales alone in 2025, per IntelMarketResearch.
Merck successfully defended its sitagliptin patents in U.S. court, securing co-formulation patent protection through at least January 2029, which may limit generic competition on the exact branded formulation.
Merck's overall business is strong and diversified: Q3 2026 revenue of ~$18.1B and raised full-year guidance to $66.8B-$67.3B, with Keytruda and Gardasil driving growth, offsetting the diabetes franchise decline.
Analyst consensus on MRK is bullish: 26 of 35 analysts rate Buy/Strong Buy, with a mean price target of $159.76 (13.4% implied upside from the $140.93 close).
▼ Bear Case5
Generic competition is already eroding sales: Par Health launched the first generic of Janumet XR in July 2026, and additional ANDA approvals for generic Janumet have been granted.
Sales are in freefall: combined JANUVIA/JANUMET sales declined 31% YoY to $429M in Q2 2026, and Q1 2026 saw a 28% decline to $574M, driven by U.S. generic competition and international pressure.
The IRA Medicare price negotiation will impose an ~85% price cut on Janumet starting January 2027, reducing the monthly cost to ~$80 from ~$527, severely compressing brand revenue.
The sitagliptin franchise faces structural headwinds beyond generics: GLP-1 receptor agonists (Ozempic, Mounjaro) and SGLT2 inhibitors are capturing market share in type 2 diabetes, permanently shrinking the DPP-4 inhibitor class.
Janumet is a small and declining part of Merck's business; its erosion is already priced in and does not represent a binary catalyst for the stock.

Upcoming Catalysts

  • IRA Medicare negotiated price for Janumet takes effect January 1, 2027 (85% cut to ~$80/month)
  • Sitagliptin phosphate salt patent expires November 24, 2026 (pediatric exclusivity to May 24, 2027)
  • Co-formulation patent expires January 21, 2029 (pediatric exclusivity to July 21, 2029)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 14

Hover a chip for the title
1 merck.com2 cnbc.com3 merck.com4 investors.parhealth.com5 accessdata.fda.gov6 accessdata.fda.gov7 gurufocus.com8 drugpatentwatch.com9 cnbc.com10 fool.com11 intelmarketresearch.com12 pharsight.greyb.com13 worldpharmaceuticals.net14 merck.com